PRE-FUNDED COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Pre-Funded Common Stock Purchase Warrant • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Securities Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or July ____, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ____, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Aspira Women’s Health Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), warrants to purchase share of Common Stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase Shares (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, Pre-Funded Warrants, and the shares of Common Stock underlying the Pre-Funded Warrants will be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-2
AMENDMENT TO COMMON STOCK PURCHASE WARRANTSCommon Stock Purchase Warrants • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 26, 2024, by and between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”).
